Luis F Barrera
Overview
Explore the profile of Luis F Barrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ocampo J, Alzate J, Barrera L, Baena A
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137331
Currently, tuberculosis (TB) is a bacterial infection caused by (Mtb) that primarily affects the lungs. The severity of active pulmonary TB (APTB) is an important determinant of transmission, morbidity, mortality,...
2.
Baena A, Cabarcas F, Ocampo J, Barrera L, Alzate J
PLoS One
. 2023 May;
18(5):e0285417.
PMID: 37205685
Mycobacterium tuberculosis (Mtb) is still one of the primary pathogens of humans causing tuberculosis (TB) disease. Mtb embraces nine well-defined phylogenetic lineages with biological and geographical disparities. The lineage L4...
3.
Lopez-Agudelo V, Baena A, Barrera V, Cabarcas F, Alzate J, Beste D, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163725
Tuberculosis (TB) is caused by (Mtb), leading to pulmonary and extrapulmonary TB, whereby Mtb is disseminated to many other organs and tissues. Dissemination occurs early during the disease, and bacteria...
4.
Alvarez-Eraso K, Munoz-Martinez L, Alzate J, Barrera L, Baena A
Curr Microbiol
. 2022 Jan;
79(2):39.
PMID: 34982251
Mycobacterium tuberculosis (Mtb) is a successful pathogen causing tuberculosis (TB) disease in humans. It has been shown, that some circulating strains of Mtb in TB endemic populations, are more virulent...
5.
Baena A, Vasco E, Pastrana M, Alzate J, Barrera L, Martinez A
Front Microbiol
. 2020 Oct;
11:537935.
PMID: 33072006
The upsurge and persistence of drug resistant strains of (Mtb) is an important limitant to the battery of drugs available for the elimination of tuberculosis (TB). To avoid future scarcity...
6.
Lopez-Agudelo V, Mendum T, Laing E, Wu H, Baena A, Barrera L, et al.
PLoS Comput Biol
. 2020 Jun;
16(6):e1007533.
PMID: 32542021
Metabolism underpins the pathogenic strategy of the causative agent of TB, Mycobacterium tuberculosis (Mtb), and therefore metabolic pathways have recently re-emerged as attractive drug targets. A powerful approach to study...
7.
Benjumea-Bedoya D, Marin D, Robledo J, Barrera L, Lopez L, Del Corral H, et al.
Colomb Med (Cali)
. 2020 Jun;
50(4):261-274.
PMID: 32476692
Aim: To assess the risk of tuberculosis (infection and disease) in children less than 15 years' old who are household contacts of pulmonary tuberculosis patients in three Colombian cities (Medellín,...
8.
Lavalett L, Ortega H, Barrera L
Front Cell Infect Microbiol
. 2020 May;
10:163.
PMID: 32391286
Monocytes play a critical role during infection with (Mtb). They are recruited to the lung, where they participate in the control of infection during active tuberculosis (TB). Alternatively, inflammatory monocytes...
9.
Lavalett L, Ortega H, Barrera L
Front Immunol
. 2020 May;
11:630.
PMID: 32373118
(Mtb) infects alveolar macrophages (AMs), causing pulmonary tuberculosis (PTB), the most common form of the disease. Less frequently, Mtb is disseminated to many other organs and tissues, resulting in different...
10.
Baena A, Cabarcas F, Alvarez-Eraso K, Isaza J, Alzate J, Barrera L
Virulence
. 2019 Jul;
10(1):695-710.
PMID: 31291814
The heterogeneity of the clinical outcome of (Mtb) infection may be due in part to different strategies used by circulating strains to cause disease. This heterogeneity is one of the...